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Negative affect is critical for conferring vulnerability to opiate addiction as reflected by the high comorbidity 
of opiate abuse with major depressive disorder (MDD). Rodent models implicate amygdala prodynorphin 
(Pdyn) as a mediator of negative affect; however, evidence of PDYN involvement in human negative affect is 
limited. Here, we found reduced PDYN mRNA expression in the postmortem human amygdala nucleus of the 
periamygdaloid cortex (PAC) in both heroin abusers and MDD subjects. Similar to humans, rats that chroni-
cally self-administered heroin had reduced Pdyn mRNA expression in the PAC at a time point associated with a 
negative affective state. Using the in vivo functional imaging technology DREAMM (DREADD-assisted meta-
bolic mapping, where DREADD indicates designer receptors exclusively activated by designer drugs), we found 
that selective inhibition of Pdyn-expressing neurons in the rat PAC increased metabolic activity in the extended 
amygdala, which is a key substrate of the extrahypothalamic brain stress system. In parallel, PAC-specific Pdyn 
inhibition provoked negative affect–related physiological and behavioral changes. Altogether, our transla-
tional study supports a functional role for impaired Pdyn in the PAC in opiate abuse through activation of the 
stress and negative affect neurocircuitry implicated in addiction vulnerability.
Introduction
Chronic negative emotional states are a compelling motivation for 
relapse to most drugs of abuse, especially opiates (1). The cluster 
of symptoms that make up these negative emotional states include 
loss of motivation for natural reward, dysphoria, anhedonia, and 
anxiety (1, 2). Persistent negative affect is also a cardinal feature 
of major depressive disorder (MDD), which is the most common 
comorbid psychiatric diagnosis with opiate addiction (3). The 
high comorbidity rate of these disorders has been hypothesized 
to be due to overlapping neurobiological abnormalities in neural 
circuits regulating emotion (4, 5).
In accordance with this hypothesis, human imaging studies of drug 
addiction and MDD patients converge on structural and functional 
disturbances in limbic neurocircuitry such as the amygdala (6–10). 
The amygdaloid complex comprises several heterogeneous nuclei 
that mediate emotional responses to fear, dysphoria, and activation 
of the brain’s stress system (11–13). Accordingly, neurotransmitters 
within the amygdala may underlie the neuropathology of MDD and 
addiction disorders and are target candidates for understanding the 
neurobiological basis of negative affect to opiate addiction.
Across species, the amygdala displays a dense expression of 
the endogenous opioid neuropeptide precursor prodynorphin 
(PDYN) (14), highly implicated in negative mood states (13, 15, 
16). Preclinical animal studies support that PDYN disturbances 
are characteristic of negative affect states in drug self-administra-
tion, stress exposure, and depression-like behaviors (17–20). Spe-
cifically within the amygdala, PDYN expression is altered by acute 
and chronic administration of heroin (18–20). Although such 
animal studies point to amygdala PDYN as a relevant factor in 
negative affect– and opiate disorder–related phenotypes, very few 
studies have investigated PDYN mRNA expression in the human 
amygdala related to neuropsychiatric disorders. Therefore, our 
goal was to investigate whether amygdala PDYN expression was 
abnormal in opiate abuse subjects and was a shared neuropatho-
logical feature of MDD. The current results highlighted a com-
mon PDYN impairment within a virtually unexplored sub-region 
of the amygdala, the periamygdaloid cortex (PAC) nucleus. This 
unusual finding prompted us to utilize a rat behavioral model 
to interrogate the in vivo functional connectivity of PAC-PDYN 
neurons using a novel molecular imaging technique.
Results
Heroin abusers and MDD subjects share a reduction of PDYN in the 
PAC. We assessed molecular alterations of amygdala PDYN gene 
expression in human opiate abusers. PDYN mRNA expression 
was evaluated using in situ hybridization histochemistry (ISHH) 
on amygdala from 2 postmortem heroin abuse cohorts: (a) an 
ethnically mixed cohort from the US (ref. 21) and Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI70395DS1); and (b) a white Hungarian popula-
tion (ref. 21 and Supplemental Table 2). Congruent with previous 
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studies (21, 22), PDYN in the human amygdala had the greatest 
expression within the nuclei of the PAC, amygdalohippocampal 
area (AHA), and accessory basal nucleus (AB) (Figure 1).
A selective reduction of PDYN mRNA expression was observed 
in the PAC of the cohort I heroin population (Figure 1A; 
nControl = 7, nHeroin = 8; P = 0.045). No other amygdala nuclei assessed 
showed any difference (Supplemental Figure 1). Similarly a second 
population of heroin abusers in cohort II displayed a specific reduc-
tion of PDYN mRNA expression in the PAC (Figure 1B; nControl = 18, 
nHeroin = 28; P = 0.037; Supplemental Figure 2). Further, no signifi-
cant correlation was found between heroin metabolites and PDYN-
PAC expression in either heroin cohort, suggesting that the PDYN 
changes were likely due to chronic heroin abuse.
Next, we examined whether amygdala PDYN disturbances were 
evident in an MDD population of the same ethnic makeup as 
heroin cohort II (Supplemental Table 3). Similar to those in both 
heroin cohorts, MDD subjects had a significant downregulation 
of PAC-PDYN mRNA expression (Figure 1C; nControl = 10, nMDD = 14; 
P = 0.030). Distinct from the heroin populations, MDD subjects 
also exhibited decreased PDYN expression in the other amygdala 
nuclei of the AB and AHA (Supplemental Figure 3).
Reduced Pdyn mRNA in the PAC and concomitant sensitization of neu-
ral stress marker induced in rats with chronic heroin self-administration. 
The shared alterations of PDYN mRNA levels in heroin abus-
ers and MDD subjects brought attention to the PAC. However, 
information about this subnucleus was limited, thus, warrant-
ing studies in animal models to help address the limitations of 
human postmortem studies such as incomplete knowledge of 
drug use history and time of death following drug use. To this 
end, we used the well-validated model of heroin self-administra-
tion in rats (23). First, we found that there was detectable Pdyn 
mRNA expression in the analogous structure of the PAC in rats 
(Figure 2A). Next we used the operant paradigm of heroin self-
administration in which animals robustly self-administered her-
oin (30 μg/kg/infusion on a designated “active” lever), but not 
saline (Figure 2B; n = 6–7 per group ANOVA, P < 0.001). After 
10 days of chronic heroin self-administration, animals were 
euthanized 24 hours after last drug use, a time point character-
ized by negative affective state and stress activation associated 
with heroin withdrawal and drug seeking (24). Figure 2C shows 
that Pdyn mRNA expression was reduced in the PAC at 24 hours 
after the last heroin session (P = 0.031, n = 5–6).
In order to verify that animals were in a heightened stress state 
24 hours after last heroin intake, we examined the expression of 
the brain stress marker corticotropin-releasing factor (Crf) within 
the central amygdala (CeA), an extrahypothalamic brain stress site. 
Increased mRNA expression of CeA Crf, has been correlated with 
the aversive motivational properties of opiate withdrawal (25) and 
was indeed apparent at the 24-hour withdrawal period (P = 0.045; 
Figure 2D; n = 5–7).
DREAMM in vivo behavioral imaging reveals a direct link of inhibition 
of PAC-Pdyn neurons with hyperactivation of the extended amygdala. Due 
to the unknown functional connectivity of PAC-Pdyn neurons in 
relation to the complex heterogeneous organization of the amyg-
dala, we used a novel strategy to identify in vivo functional brain 
circuits associated with modulation of PAC-Pdyn neuronal activ-
ity (Supplemental Methods). This technique, entitled DREAMM, 
integrates viral-mediated designer receptors exclusively activated 
by designer drugs (DREADD) (26) and metabolic mapping using 
a direct marker of brain metabolism, [18F]Fluorodeoxyglucose 
(FDG) and μPET imaging. (27).
Rats were unilaterally infused in the right PAC with a 
neuronal Pdyn promoter-specific DREADD viral construct that 
encodes expression of a Gi-coupled receptor (hM4Di) solely 
activated by the otherwise inert pharmacological substance, 
clozapine-n-oxide (CNO) (Supplemental Figure 4) (26, 28). 
CNO binding to the hM4Di-Pdyn DREADD receptor activates 
Gi-mediated signaling, leading to a transient inhibition of Pdyn 
neuronal firing (26, 28). FDG uptake occurred in behaving 
animals, and rats were scanned in 2 states: following vehicle or 
CNO. As compared with the vehicle state, CNO administration 
and subsequent reduction of PAC-Pdyn neuronal activity led to 
a strong increase (P < 0.05) of FDG uptake in the ipsilateral 
(right) macrostructure known as the extended amygdala (ExA) 
Figure 1
PDYN is reduced in the PAC of postmortem chronic heroin subjects and MDD subjects. (A–C) Representative film autoradiograms of PDYN 
mRNA expression on coronal cryosections of the amygdala and corresponding bar graphs of PDYN mRNA expression levels in the PAC. Values 
are expressed in DPM/mg (mean ± SEM) and the PAC is encircled in red. Scale bar: 5 mm (A) Cohort I of heroin abusers and matched controls. 
(B) Cohort II of heroin abusers and matched controls. (C) MDD subjects and matched controls. *P < 0.05.
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(Figure 3A; Supplemental Figure 5). The ExA is a functional 
circuit associated with negative affect and stress that consists 
of the medial amygdala (MeA), CeA, bed nucleus stria termi-
nalis (BNST), and nucleus accumbens (NAc) shell (Figure 3B; 
Supplemental Figure 5) (29).
To validate the specificity of this global ExA activation, we quan-
tified individual responses based on voxel intensity in the discrete 
substructures of the ExA, including the BNST, CeA, MeA, and 
NAc shell (Figure 4A). Administration of CNO versus vehicle sig-
nificantly increased voxel intensity within the majority of the right 
ExA components with a trend in the CeA, ipsilateral to the site 
of injection (BNST, P = 0.002; right NAc shell, P = 0.031; MeA, 
P = 0.008; CeA, P = 0.1; Figure 4B). The percentage increases (3%–10%) 
in voxel intensity of FDG uptake are within the range associated 
with physiological and clinical changes in humans (30–32) and 
with lesions of the susbtantia nigra in rodents (33).
Inhibitory modulation of PAC-Pdyn neurons induces depression-related 
behavioral and physiological phenotypes. The ExA as a circuit and its 
individual components are strongly implicated in aversive state 
and serves as an interface between stress and addiction (1). As 
such, we next evaluated behavioral and physiological parameters 
of stress in PAC-hM4Di-Pdyn animals. First, we found that CNO 
administration in PAC-hM4Di-Pdyn rats led to significantly ele-
vated corticosterone levels as compared with vehicle administra-
tion in the same animal (P = 0.014; Figure 5A) and this effect 
was not attributable to the order of CNO administration, as the 
animals were counterbalanced (P = 0.93). No effect of CNO was 
observed in control PAC-GFP-Pdyn animals (Supplemental Fig-
ure 6). Hedonic state was examined using the sucrose preference 
task in animals expressing either PAC-hM4Di-Pdyn or PAC-GFP-
Pdyn (control). CNO administration led to a decrease in sucrose 
consumption in PAC-hM4Di-Pdyn animals as compared with 
control GFP-Pdyn (P = 0.032; Figure 5B). Last, depressive-like 
phenotype was assessed using the forced swim test, a commonly 
used depression model of behavioral despair (34). Rats express-
ing either PAC-hM4Di-Pdyn or PAC-GFP-Pdyn were exposed to a 
15-minute swim pretest 24 hours before the test. On test day, ani-
mals were evaluated for 5 minutes and time spent immobile was 
scored. PAC-hM4Di-Pdyn animals displayed significantly higher 
immobility as compared with control rats, which was indicative 
of increased depression-like behavior (n = 7/group, P = 0.003; Fig-
ure 5C). This impairment was not due to a gross motor deficit, 
as there was no significant difference between hM4Di-Pdyn and 
PAC-GFP-Pdyn animals in overall locomotor behavior assessed in 
an open field (Supplemental Figure 7).
Discussion
Using a translational approach, we have shown that impaired 
PDYN mRNA expression in the human PAC is a shared character-
istic of the diagnostically distinct but symptomatically related dis-
orders of opiate addiction and MDD. The consistent disturbance 
of PAC-PDYN expression is intriguing but raises questions as to 
the potential functional relevance of this impairment, since the 
PAC, unlike other amygdala nuclei, has not been extensively stud-
ied. As such, we expanded insights about the PAC-Pdyn neurons 
by examining their in vivo functional connectivity. Our use of the 
molecular in vivo imaging strategy DREAMM in rats highlighted 
the selective recruitment of the ExA in relation to impaired PAC-
Figure 2
Reduced Pdyn mRNA in the PAC and concomitant sensitization of a neural stress marker induced in rats with chronic heroin self-administration. 
(A) Rodent PAC schematic and in situ hybridization image of Pdyn in the PAC. Scale bar: 2 mm. (B) Lever-pressing behavior (active versus 
inactive lever presses) of rats receiving heroin or saline euthanized 24 hours after last self-administration session. Data shown as mean ± SEM. 
*P < 0.05 between active lever (AL) and inactive lever (IL) presses of animals receiving heroin. #P < 0.05 in active lever presses between heroin 
and saline animals. (C) Reduction of PAC-Pdyn mRNA expression in rats 24 hours after final heroin self-administration session versus saline 
animals. Data represent mean ± SEM, fold change difference. *P < 0.05. (D) Increased Crf mRNA expression in the CeA 24 hours following 
heroin self-administration. Values are expressed in DPM/mg (mean ± SEM). *P < 0.05.
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Pdyn neuronal activity, therefore linking the Pdyn in the PAC to a 
functional neural network that regulates negative affect responses 
relevant to opiate addiction vulnerability.
Our finding of an association between the Pdyn system and neg-
ative affect is in line with a large body of evidence. While much of 
the published data have been obtained from experimental animal 
studies (15, 16, 35), recent clinical investigations have also dem-
onstrated that variants of the PDYN gene relate to transcriptional 
alterations of PDYN mRNA expression and are associated with 
depressive traits and negative craving in alcoholics (36, 37). The 
current study adds to the field by directly examining the human 
brain to provide neuropathophysiological insights that have not 
been previously reported. The shared reduction of PDYN mRNA 
expression in the amygdala PAC of human heroin and MDD sub-
jects supports the hypothesis that common disturbances in brain 
areas linked to emotional regulation underlie the high comorbid-
ity rates of drug addiction with MDD. Although human postmor-
tem studies have many challenges, the PDYN mRNA impairments 
observed were replicated in multiple cohorts of opiate abusers and 
disturbances detected in the MDD subjects also matched those 
previously reported (38). In addition, unlike the PAC, where PDYN 
expression was similarly reduced in addiction and MDD subjects, 
PDYN mRNA is differentially affected in the striatum of presum-
ably depressed suicide subjects (39) and heroin abusers (40).
The prevailing hypothesis in the field posits that increased dyn-
orphin mediates negative affect. While the reduction of PDYN 
mRNA expression observed in the current study might seem con-
trary, there may be compensatory upregulation of peptide levels. 
Indeed, it has been demonstrated in the striatum that reduced 
PDYN mRNA expression can occur concomitant to elevated dyn-
orphin levels in some heroin abusers (40). Future insights about 
the release of PDYN-derived peptides from PAC-PDYN neurons 
will be very informative. It is also important to emphasize that 
the relationship between PDYN and different aspects of negative 
affect is complex and still requires further investigation. For exam-
ple, although stress-induced aversion is established to be mediated 
by elevated dynorphin (41, 42), a number of investigations have 
documented that animals lacking the Pdyn gene have enhanced 
anxiety behavior (43, 44). Moreover, our study underscores the het-
erogeneity of PDYN expression even within discrete brain regions, 
suggesting different PDYN circuits could contribute to distinct 
behavioral components relevant to negative affect.
A notable finding in the present study was that MDD subjects, 
in addition to the PAC, also had reduced PDYN mRNA expression 
in the AB and AHA nuclei. These disturbances were not, however, 
evident in the lateral nucleus (Supplemental Figure 3), which also 
expresses PDYN, suggesting that the alterations in MDD individu-
als are not global but instead discretely localized. Further studies are 
needed to delineate the specific contribution of PDYN AB and AHA 
neurons to distinct components of MDD neuropathophysiology.
Direct molecular studies of the human brain are of marked impor-
tance, but some limitations of human postmortem investigations are 
the lack of complete knowledge about the subjects’ drug abuse and 
other confounding factors, including nicotine consumption, medical 
history, and time of last drug use prior to death, which are relevant 
for interpretation of the data. However, interestingly, a reduction of 
PAC-Pdyn mRNA expression was also found in rats that self-adminis-
tered heroin at a time point associated with acute withdrawal related 
Figure 3
DREAMM imaging reveals that neuronal inhibition of Pdyn neurons in the PAC increases metabolic activity in the ExA. (A) Axial and right sagittal 
views showing that activation of Gi-mediated signaling in Pdyn neurons of the PAC with CNO leads to a profound induction of neuronal activity 
primarily in the right ExA as compared with vehicle administration in the same animal (red, relative increase; blue, relative decrease). LH, lateral 
hypothalamus; NAcSh, NAc shell; SI, substantia inominata; VMH, ventral medial hypothalamus; IPAC, interstitial nucleus of posterior limb of 
anterior commissure; SC/MC, sensory cortex/motor cortex; ON, olfactory nuclei; CeA, central amygdala; MVePC,: medival vestibular nucleus, 
parvicellular part; VP, ventral pallidum; LEnt, lateral entorhinal cortex; BLA, basolateral amygdala; MPA, medial preoptic area. (B) Schematic 
diagram of the ExA circuit and its substructures.
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to hyperactivation of brain stress systems (upregulation of Crf expres-
sion in the CeA). Indeed, extracellular and mRNA Crf changes in the 
CeA are consistently associated with acute withdrawal from opiates 
(25, 35, 45). Our human data also underscore the importance of the 
PAC-PDYN alterations related to chronic neuroadaptations, given 
that acute toxicology of heroin metabolites did not correlate with 
amygdala PDYN expression. Altogether, these observations are in line 
with PAC-PDYN impairments underlying negative affect that may 
contribute to the motivational drive for drug-seeking and relapse 
behavior and that have been associated with a decrease in the func-
tion of neuronal reward circuits that contributes to addiction, which 
Koob et al. have characterized as the “dark side” of addiction (46).
Our use of the innovative molecular and in vivo imaging strat-
egy of DREAMM in rats also clearly highlighted the striking selec-
tive association of PAC-Pdyn neurons with the ExA that serves 
as an interface between drug abuse and negative affect (13, 47). 
Moreover, the fact that impaired firing of Pdyn neurons directly 
enhanced corticosterone levels and also induced behavioral anhe-
donia and despair provides strong evidence for a direct causal rela-
tionship between PAC-Pdyn neuronal function and negative affect. 
Recent imaging studies in humans and primates have expanded 
the concept of the ExA in higher order species and support a role 
for its dysfunction in responses to antidepressants (48, 49). As 
such, the activation of the ExA due to inhibition of Pdyn neurons 
in the PAC of behaving animals suggests that chronic PAC-Pdyn 
dysregulation may be relevant to relapse that is driven by enhanced 
negative affect/stress/anxiety that maintains the insidious cycle of 
drug abuse. Further studies are needed to determine whether PAC-
Pdyn neurons are a feasible target for addiction-related behaviors, 
particularly during the withdrawal phase.
It is important to note that species differences exist in the expres-
sion pattern of Pdyn in the amygdala of humans and rodents. 
Whereas humans have pronounced Pdyn expression in cortical 
amygdala nuclei such as the PAC and in the AB (22), rodents have 
the strongest expression in the CeA, basolateral, and medial nuclei 
(50). Despite the species difference, the PAC circuitry variations 
examined in several primate and nonprimate models have been 
shown to be complementary (51, 52). As such, the similar changes 
in PAC-Pdyn observed in the rodent heroin self-administration 
model and in human heroin abusers would be predicted to affect 
similar types of neural circuitry.
Overall, the common disturbance of PDYN in the PAC in opiate 
addiction and MDD offers new pathophysiological insights into 
the amygdala relevant to stress and negative affect endopheno-
types common in opiate addiction. Moreover, the in vivo imag-
ing technique of DREAMM to manipulate neurochemically dis-
tinct cells in discrete brain areas with high molecular specificity 
in awake freely moving animals will be a valuable neurobiological 
tool in helping to enhance knowledge about discrete neuronal cir-
cuits relevant to neuropsychiatric disorders.
Methods
Human postmortem subjects
Cohort I heroin abuse population. The postmortem human brain specimens used 
for this population were previously described (21). Briefly, specimens from her-
oin users and nonabuse control subjects were collected within 24 hours after 
death. The brains were immediately frozen using dry-ice–cooled isopentane, 
subsequently cryosectioned, and thaw-mounted onto poly-l-lysine–treated 
slides. Cause and manner of death were determined after medico-legal exami-
nation by the medical examiner. Demographics of this cohort are described 
in Supplemental Table 1. Inclusion criteria were death associated with heroin 
intoxication, as verified by toxicology, physical signs of heroin use such as 
needle track marks, and a history of heroin abuse. Exclusion criteria for all 
subjects were postmortem interval (PMI) of greater than 24 hours, age less 
than 50 years, HIV-positive status, and history of alcoholism. Positive alcohol 
was evident in some of the controls and heroin subjects; however, ethanol con-
centrations in both groups were not significantly different.
Figure 4
Voxel analysis of ExA substructures confirms increase of metabolic activity following PAC-Pdyn inhibition. (A) Representative coronal images 
of ExA substructures analyzed for voxel analysis (B) Quantitative bar graphs of 3D voxel intensities in the right ExA substructures. Evaluation of 
each substructure demonstrated that CNO administration enhanced voxel intensity selectively in the right substructures as compared with vehicle 
administration. BNST, P = 0.002; NAc shell, P = 0.031; MeA, P = 0.008; CeA, P = 0.1, paired t test.
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Cohort II heroin abuse and MDD populations. Postmortem human brain speci-
mens from white Hungarian subjects were collected for 3 study populations: 
(a) heroin abusers, (b) those who committed suicide by hanging with a diag-
nosis of MDD, and (c) healthy control subjects. All specimens were without 
head trauma and retrieved at autopsy within 24 hours after death. The brains 
were collected and stored similarly to those from cohort I. The demograph-
ics and general characteristics for cohort II are described in Supplemental 
Tables 2 and 3. All cases were assessed for common drugs of abuse (including 
alcohol and marijuana) and also for therapeutic agents. Cigarette toxicology 
was not assessed, but cigarette use was common for subjects in all groups.
Subjects in the MDD group had a verified psychiatric history and diag-
nosis of depression and had no documented history or positive toxicology 
for illicit drug abuse. The same control group was used for both heroin 
and MDD cohort II subjects (but studied in separate experiments), since 
the brains of these individual cadavers were collected during the same time, 
were ethnogeographically similar, and adhered to the following criteria: 
negative toxicology of illicit drugs and antidepressants; no history of illicit 
drug abuse or mood and anxiety disorders. Positive alcohol was evident in 
very few controls in which ethanol concentrations were similar to those of 
the limited alcohol-positive subjects identified in the heroin group (none 
of the MDD subjects were alcohol positive). Exclusion criteria for all sub-
jects were as follows: PMI greater than 24 hours, age greater than 50 years, 
HIV-positive status, and history of alcoholism.
ISHH
Briefly, as previously described, riboprobes complementary to the human 
PDYN gene were synthesized from a 1.2-kb human cDNA from the main 
exon of the PDYN gene (38). The Crf riboprobe used for the rat tissue was 
a 760-bp cDNA fragment of the gene (1196 bases; GenBank 81648). ISHH 
was performed on 20-μM coronal cryosections of human or rodent amyg-
dala specimens as previously described (38). The high quality of the post-
mortem human brain samples suitable for mRNA expression studies is 
evident in our ability to routinely detect mRNAs of various genes in these 
samples (21, 40, 53, 54).
Image analysis
Optical density values were measured using Scion Image (NIH) from digi-
talized images or FujiFilm Multigauge V3.0 from phosphofilm exposed 
slides. Measurements were converted to disintegrations per minute 
(DPM)/mg by reference to coexposed C14 standards. Measurements were 
taken within discrete amygdala subnuclei at similar levels according to pre-
viously published data on the human brain (38). Background noise was 
also measured and subtracted from the measurements taken. DPM/mg 
values from duplicate slides were averaged.
Animal studies
Adult (PND 55-69) male Long-Evans rats were obtained from Charles River 
Laboratories and housed on a reversed 12-hour dark/12-hour light cycle 
with food and water available ad libitum except as noted below.
Heroin self-administration
Rats were anesthetized with isoflurane (2.5%–4.0% in O2) and catheters (Brian 
Fromant) implanted into the right jugular vein. Following 1 week recovery, 
the heroin self-administration paradigm was initiated as previously described 
(55). Briefly, self-administration experiments were conducted during the dark 
phase of the light/dark cycle in standard operant chambers housed in sound-
attenuating boxes (MED Associates Inc.) with 2 retractable levers. Depression 
of the drug-paired lever (defined as the active lever) resulted in an intravenous 
heroin (NIDA Drug Supply) injection, whereas depression of the inactive lever 
had no programmed consequence. Rats were allowed to self-administer heroin 
(30 μg/kg/injection) under a fixed-ratio-1 (FR1) reinforcement schedule in 
daily 3-hour sessions for 10 days. Brains were collected at 24 hours following 
the final drug self-administration session.
Quantitative PCR gene expression
Fresh-frozen bilateral 12-gauge punches were taken from the rat posterior 
medial lateral cortical (PM/LCo) nuclei equivalent of the PAC; total RNA was 
isolated using the 5 Prime PerfectPure RNA Tissue Kit and reverse transcribed to 
cDNA (qScript Kit; VWR). Quantitative real-time PCR (qPCR) analysis was per-
formed using TaqMan-based Pdyn primers and probes (Pdyn Rn00571351_m1; 
Applied Biosystems). Reactions were run in triplicate, and eukaryotic 18S 
rRNA (Applied Biosystems) multiplexed as an endogenous control. qPCR and 
subsequent analysis were performed with a Roche Light Cycler 480 sequence 
detection system. Quantification of Pdyn gene expression was normalized to 
eukaryotic 18S rRNA and analyzed using the ΔΔCT method (56).
Viral-mediated DREADD expression
All rats were stereotaxically injected with 2 μl (0.2 μl/min) of purified 
herpes simplex virus (HSV) vectors expressing a triple hemagglutinin 
(HA) epitope-tagged hM4Di gene (1567 Kb) under the control of the 
Figure 5
Inhibitory modulation of PAC-Pdyn neurons induces depression-related behavioral and physiological phenotypes. (A) There is a significant 
increase in corticosterone levels in PAC-Pdyn-hM4Di rats administered CNO as compared with vehicle administration in the same animal. Values 
represent ng/ml, *P < 0.05. (B) PAC-Pdyn-hM4Di animals consumed significantly less sucrose than PAC-Pdyn-GFP animals (P = 0.032, ANOVA) 
although they did not differ in water consumption. Data are shown in ml, *P < 0.05 (C) PAC-Pdyn-hM4Di rats show increased immobility compared 
with Pdyn-GFP animals in the forced swim test. Data represent cumulative time in seconds, **P < 0.01.
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Pdyn promoter (PAC-hM4Di-Pdyn) or a control vector that expresses 
GFP, also under the control of the Pdyn promoter (PAC-GFP-Pdyn) (28). 
The vectors were injected unilaterally (right hemisphere) into the PAC 
(PM\LCo) using the following coordinates (from bregma): AP, –4.3; ML, 
3.7; DV, 9.6 mm.
DREAMM
The DREAMM technique was conducted as described in Supplemental 
Methods. Rats received an i.p. injection of either vehicle-saline or the DRE-
ADD-activating ligand CNO (7–10 days post vector injection) (1 mg/kg). 
Immediately after vehicle or CNO injection, rats were injected i.p. with 
FDG (∼0.6 mCi). Order of CNO administration was counterbalanced in 
animals due to the within subjects design of the experiment. Thirty min-
utes later, rats were anesthetized with 1.5% isoflurane, placed in a prone 
position on the bed of an R4 microPET rodent scanner (Siemens Medi-
cal Solutions), and scanned for 20 minutes using a static acquisition pro-
tocol. Analysis of the scans, reconstruction of the images, and statistical 
parametric mapping (SPM) were conducted as described in Supplemental 
Methods. Briefly, anatomical regions were based on Paxinos coordinates, 
and sites of voxel analysis were validated in conjunction with a rat brain 
imaging atlas intrinsic to the analytical software.
Corticosterone assessment
Whole blood was obtained from a tail-vein catheter under isoflurane anes-
thesia in hM4Di-Pdyn rats (given either 1 mg/kg of CNO or vehicle i.p. thirty 
minutes prior to anesthesia). After centrifugation, the remaining superna-
tant (plasma) was stored at –80°C. Levels of corticosterone were measured 
from the blood plasma using the IDS Corticosterone HS EIA kit (Immuno-
diagnostics Systems) according to the manufacturer’s instructions.
Sucrose preference test
To measure anhedonic traits, the sucrose preference test was carried out in 
hM4Di-Pdyn or GFP-Pdyn rats. Rats were given the choice of drinking from 
2 bottles, one of which contained a 1% sucrose solution and the other of 
standard water. Baseline sucrose preference of each animal was determined 
over a 24-hour period prior to the test. Subsequently, animals were food 
and water restricted for 15 hours prior to the test session. One hour prior 
to the test session, all animals (hM4Di-Pdyn or GFP-Pdyn) received 1 mg/kg 
i.p. of CNO. Choice preference was observed over 24 hours.
Forced swim test
The procedure used was based on that initially described by Porsolt and 
modified as described (34). Behavioral studies were carried out from 
11:00 to 17:00. Rats were placed individually in a Plexiglass cylinder 46 
cm in height with a 21-cm internal diameter, which was filled with water 
(23°C–24°C) to a depth sufficient to keep adult rats from supporting 
themselves by placing their paws or tails on the base of the cylinder. Water 
was changed between swim sessions. There were 2 swim sessions: a pretest 
15-minute session and, 24 hours after, a 5-minute swim test. The cumula-
tive time spent in immobile posturing (minimal effort to keep head above 
water) during the 5-minute test was recorded.
Open field/locomotor activity
Prior to testing, rats were acclimated to the test room for 1 hour. General 
locomotor activity was examined in a MED Associates activity arena 
(16 in. × 16 in.) outfitted with a grid of 32 infrared beams. All movements 
were automatically tracked by beam breaks in 1-hour sessions run in dim 
lighting for each subject. Between animals, all cages were thoroughly wiped 
clean with ethanol followed by vinegar.
Statistics
For ISHH, parametric univariate analysis for normal distribution was used to 
determine group differences in DPM/mg levels. Independent variables (age, 
PMI, sex, toxicology [prescription and illicit], and brain pH] were included in 
the general linear model if results from univariate analysis (ANOVA) showed 
a P value of less than 0.05. For unequal variances (as determined by the 
2-sided F test), Welch’s test was used to determine P value. We used 2-tailed, 
unpaired Student’s t tests (for comparison of 2 groups), 1-way ANOVAs fol-
lowed by Tukey’s honest significant difference test or 2-tailed Student’s t 
tests when appropriate (for 3 groups), and 1-way repeated-measures ANO-
VAs followed by 1-way ANOVAs (to examine significant repeated-measure 
effects). All values represent mean ± SEM. P > 0.05 and statistical calculations 
were performed using JMP software (SAS) or GraphPad Prism 5.0.
Study approval
Postmortem human brains for cohort I were obtained as part of the rou-
tine autopsy process under protocols approved by Wayne State University’s 
Human Investigation Committee. Postmortem human brains in cohort II 
were obtained through the Department of Forensic Medicine at Semmelweis 
University and from the National Institute of Forensic Medicine (Karolinska 
Institutet). All of the specimens from cohort II were collected under guide-
lines approved by the Semmelweis University Research Ethical Committee 
and the Karolinska Institute Research Ethical Committee. All animal experi-
ments were approved by the institutional animal care and use committees 
at the Icahn School of Medicine at Mount Sinai and Brookhaven National 
Laboratory and were conducted in accordance with NIH guidelines.
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